ANI Pharmaceuticals ANIP Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $29.49M+88.1% | $27.49M+368% | $26.62M+210% | $8.55M+474% | $15.68M-13.9% | ||
| $20.92M-8.6% | $22.61M+0.1% | $22.63M+43.7% | $23.28M+58.4% | $22.89M+55.9% | ||
| $10.19M+14.9% | $9.77M+38.3% | $9.69M+29.5% | $9.6M+22.1% | $8.87M+27.9% | ||
| $2.52M+174% | $2.36M+113% | $18.8M+436% | -$3.54M-86.2% | -$3.38M-209% | ||
| $358K+10.5% | $351K+8.7% | $340K+181% | $341K+255% | $324K+218% | ||
| -$25.53M-1,333% | $27.86M+9.2% | $26.97M+420% | $5.49M— | -$1.78M-117% | ||
| $437K-30.1% | —— | $8.16M+28.3% | $908K-92.2% | $625K-76.3% | ||
| $5.36M-3.4% | —— | $13.77M— | $3.08M— | $5.55M-51.9% | ||
| -$2.69M-168% | $4.46M— | $6.45M+416% | -$9.84M-2,220% | $3.95M+392% | ||
| $14.09M+89.4% | $0— | -$12.55M-288% | -$10.89M+23.7% | $7.44M+130% | ||
| $5.75M+725% | $273K— | $3.14M+132% | $332K+112% | -$921K-110% | ||
| $453K+0.2% | $555K+41.6% | $358K-6.8% | $394K+4.5% | $452K+21.2% | ||
| $58.38M+66.8% | $30.37M+91.5% | $44.06M+253% | $75.81M+335% | $34.99M+91.5% | ||
| $6.07M+146% | $1.24M-48.0% | $6.1M+26.8% | $4.01M-9.8% | $2.47M-46.0% | ||
| $5.25M-69.8% | $159K+84.9% | $60K-90.5% | $2.9M— | $17.37M— | ||
| -$11.32M+42.9% | -$1.4M+86.9% | -$6.16M+98.5% | -$6.91M-55.3% | -$19.85M-322% | ||
| $0-100% | $0-100% | $344K-15.3% | $407K0.0% | $406K0.0% | ||
| $19.76M+97.5% | $611K+92.1% | $1.04M+53.5% | $551K-57.6% | $10M+15.5% | ||
| $4.06M+100% | -$6.09M-102% | $2.03M— | $2.03M+171% | $2.03M+171% | ||
| $2.2M-13.1% | -$13.57M— | $9.79M— | $1.24M+148% | $2.53M-2.2% | ||
| -$21.62M-118% | -$4.64M— | —— | -$1.75M-20.3% | -$9.91M+49.8% | ||
| $156K+153% | -$1.35M-243% | $576K+868% | $841K— | -$297K— | ||
| $25.59M+418% | $22.98M+18,779% | $44.81M+147% | $68M+491% | $4.94M-33.9% | ||
| $7.82M-12.0% | $4.61M-10.4% | $8.46M+175% | $4.97M-39.5% | $8.9M+11.9% | ||
| -$6.07M-2,228% | $1.06M-42.6% | $140K+1,300% | $16.19M-1.0% | $285K-66.5% | ||
| $358K+10.5% | $351K+8.7% | $340K+181% | $341K+255% | $324K+218% | ||
| -$182K+98.5% | -$5.73M-203% | -$14.47M-1,854% | $0-100% | -$12.09M-13,536% | ||
| -$4.74M-221% | $6.12M-19.8% | $4.17M+355% | $10.22M+263% | $3.93M+248% | ||
| -$2.69M-168% | $4.46M— | $6.45M+416% | -$9.84M-2,220% | $3.95M+392% | ||
| -$6.45M-302% | $0-100% | $1.32M+1,617% | $6.22M+495% | $3.19M+0.5% | ||
| -$14.66M-1,448% | —— | $15.22M+392% | $12.32M+152% | $1.09M+236% | ||
| -$21M-23.0% | $5.62M+3.3% | —— | —— | -$17.08M-30.6% | ||
| $453K+0.2% | $555K+41.6% | $358K-6.8% | $394K+4.5% | $452K+21.2% | ||
| $20.92M-8.6% | $22.61M+0.1% | $22.63M+43.7% | $23.28M+58.4% | $22.89M+55.9% | ||
| $5.25M-69.8% | $159K+84.9% | $60K-90.5% | $2.9M— | $17.37M— | ||
| $784K-23.3% | $21K— | $741K— | —— | $1.02M-16.4% | ||
| $1.09M— | —— | —— | —— | $0— | ||
| -$6.07M-2,228% | —— | —— | —— | $285K— | ||
| $52.3M+60.8% | $29.12M+116% | $37.95M+395% | $71.8M+454% | $32.52M+138% | ||
| $52.3M+60.8% | $29.12M+116% | $37.95M+395% | $71.8M+454% | $32.52M+138% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does ANI Pharmaceuticals's cash flow data come from?
- Every line is extracted from ANI Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.